PA
PAB.AU PATRYS Ltd
- Market cap
- AUD 8.41M
- P/E
- -
- P/B
- 18.34x
- ROE
- -33.5%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PAB.AU undervalued?
Graham numberThe Graham number of PATRYS Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PATRYS Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-33.5%), below 10%.
ROA 1/1
Return on assets (-30.8%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-611.6%) is below the industry median (-5.3%).
Revenue Growth 0/2
Revenue shrank 85.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (18.3x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
PATRYS Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the bi…
Full company profilePATRYS Ltd financial statements
PATRYS Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 53.3K | 521K | 844K | 27.5K | 27.5K | 27.5K | 2.85M | 1.39M | 829K | 8.99K |
| Gross Profit | 532K | 521K | 844K | 773K | 1.34M | 3.33M | 2.80M | 1.39M | 829K | 8.99K |
| Operating Income | -2.36M | -2.50M | -3.41M | -3.49M | -5.86M | -11.4M | -9.86M | -3.54M | -2.71M | -3.42M |
| EBITDA | -1.42M | -2.90M | -3.36M | -3.32M | -5.69M | -11.5M | -9.79M | -3.49M | -2.66M | -3.42M |
| Net Income | -1.06M | -2.50M | -411K | -2.75M | -4.06M | -6.78M | -7.06M | -3.54M | -3.01M | -3.41M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 3.16M | 7.97M | 7.93M | 5.38M | 12.9M | 14.0M | 7.52M | 4.16M | 1.74M | 11.1M |
| Total Liabilities | 496K | 682K | 637K | 498K | 850K | 543K | 687K | 691K | 1.01M | 919K |
| Shareholders' Equity | 2.66M | 7.29M | 7.30M | 4.88M | 12.0M | 13.4M | 6.84M | 3.47M | 733K | 10.2M |
| Cash & Short-term Investments | 1.91M | 6.61M | 6.47M | 3.98M | 10.9M | 9.82M | 4.05M | 2.24M | 742K | 3.36M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.28M | -2.09M | -129K | -2.50M | -3.88M | -8.68M | -5.78M | -1.82M | -1.77M | -2.17M |
| Capital Expenditure | 2.77K | 4.13K | 4.06K | 3.89K | 3.89K | 2.29K | 0.00 | 3.24K | 2.00 | 3.85K |
| Free Cash Flow | -1.28M | -2.09M | -133K | -2.50M | -3.88M | -8.68M | -5.78M | -1.82M | -1.77M | -2.17M |
| Ratios | ||||||||||
| ROE | -39.7% | -34.2% | -5.6% | -56.3% | -33.7% | -50.5% | -103.3% | -102.0% | -411.2% | -33.5% |
| ROA | -33.5% | -31.3% | -5.2% | -51.1% | -31.5% | -48.5% | -93.8% | -85.0% | -173.3% | -30.8% |
| Net Profit Margin | -1,986.1% | -479.8% | -48.7% | -9,994.7% | -14,774.3% | -24,655.9% | -247.6% | -253.9% | -363.7% | -38,003.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PATRYS Ltd dividends
PATRYS Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:15 on Oct 13, 2025.
Who owns PATRYS Ltd
- Insiders 30.17%
- Institutions 0.00%
- Public & others 69.83%
- Shares outstanding 341M
- Free float 329M
PATRYS Ltd company profile
- Company name
- PATRYS Ltd
- Ticker
- PAB.AU
- ISIN
- AU000000PAB9
- Exchange
- Australian Securities Exchange
- Listed since
- Jul 20, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 168 Stirling Highway, Nedlands, WA, Australia, 6009
- Phone
- 61 8 6165 8858
- Website
- patrys.com
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
PATRYS Ltd management
3- Dr. Samantha South GAICD, MBA, Ph.D.Chief Executive Officer
- Mr. Johnathon Busing C.A.Joint Company Secretary
- Mr. Kieran Witt C.A.Joint Company Secretary